1767.2000 -14.10 (-0.79%)
NSE May 08, 2025 15:31 PM
Volume: 2.6M
 

1767.20
-0.79%
Phillip Capital
8 Given the +ve volume surprise in gGleevec and strong Taro performance, SUNP's Q4 earnings is 19% below our estimates. This implies weaker operating performance by SUNP'sbasebusinessandrelativelyweakerinventorypushingGleevec....
Number of FII/FPI investors increased from 1310 to 1351 in Mar 2025 qtr.
More from Sun Pharmaceutical Industries Ltd.
Recommended